Abstract | BACKGROUND: METHODS: RESULTS:
Methemoglobinemia (median methemoglobin level = 9.0% [3.5-22.4]) was documented in 32 (19.8%) patients. There was a 73% risk reduction in methemoglobinemia with dosing ≥20% below the target dose of 2 mg/kg/d (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.09-0.78; P = .016), whereas methemoglobinemia risk was increased with dosing ≥20% above the target dose (HR, 6.25; 95% CI, 2.45-15.93; P < .001). Sex, body mass index, and age were not associated with increased risk. Cytochrome b5 reductase enzyme activity did not differ by methemoglobinemia status (median 8.6 IU/g hemoglobin [Hb]; [5.5-12.1] vs 9.1 IU/g Hb; [6.7-12.7]). No patient developed PCP on dapsone. CONCLUSIONS:
|
Authors | Adam J Esbenshade, Richard H Ho, Ayumi Shintani, Zhiguo Zhao, Lesley-Ann Smith, Debra L Friedman |
Journal | Cancer
(Cancer)
Vol. 117
Issue 15
Pg. 3485-92
(Aug 01 2011)
ISSN: 1097-0142 [Electronic] United States |
PMID | 21246536
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2011 American Cancer Society. |
Chemical References |
- Anti-Infective Agents
- Dapsone
|
Topics |
- Anemia, Aplastic
(therapy)
- Anti-Infective Agents
(adverse effects)
- Child
- Child, Preschool
- Cohort Studies
- Cross-Sectional Studies
- Dapsone
(adverse effects)
- Dose-Response Relationship, Drug
- Female
- Hematologic Neoplasms
(therapy)
- Humans
- Male
- Methemoglobinemia
(chemically induced)
- Multivariate Analysis
- Pneumonia, Pneumocystis
(prevention & control)
- Proportional Hazards Models
|